Abstract
Abstract FBRSL1 is a novel protein and a member of a heterogeneous group of proteins that form polycomb repressive complex 1 (PRC1). The canonical function of PRC1 is monoubiquitination of H2A at lysine 119 which has been associated with nucleotide excision repair of UV-induced DNA lesions; however, the role FBRSL1 plays in the PRC1 complex is unknown. Additionally, single nucleotide polymorphisms residing in FBRSL1 have been shown to modify melanoma risk following indoor tanning. Since very little is known about the function of FBRSL1, the connection between FBRSL1 and melanoma is unclear. To investigate FBRSL1 expression in relationship to melanoma, we performed an immunohistochemistry (IHC) pilot study, using antibodies against both the long and short forms of murine FBRSL1, on a small set of melanoma tumor and benign patient tissues. Our results indicate that both murine antibodies recognize FBRSL1 in human skin. The FBRSL1 amino acid sequence is highly conserved between mice and humans, but only the long isoform has been validated in humans indicating that further characterization of the human isoforms of FBRSL1 is needed. Additionally, we found FBRSL1 expression only in melanoma tissues, and not in benign tissues. Future directions include validating these results in a larger group of patients using both melanoma and benign tissues to confirm the relationship between FBRSL1 expression and melanoma. Ultimately, we will investigate the association between FBRSL1 and patient characteristics that modify melanoma risk and prognosis. We expect that these results will inform experiments to elucidate the role of FBRSL1 in melanoma. Citation Format: Jenna Marie Lilyquist, Pedro Lee, Marianne Berwick, Danny Reinberg. A pilot study of FBRSL1 and melanoma: What's the connection. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1294. doi:10.1158/1538-7445.AM2014-1294
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call